TIAF-1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the TIAF-1 protein, which plays a significant role in regulating gene expression and cellular responses to stress. TIAF-1, a member of the transcription factor family, is involved in various biological processes, including cell growth, differentiation, and apoptosis. These inhibitors function primarily by binding to key regions of the TIAF-1 protein, such as its DNA-binding domain or other critical sites necessary for its interaction with DNA and transcriptional machinery. By occupying these essential regions, TIAF-1 inhibitors effectively block the protein's ability to bind to specific DNA sequences, disrupting its role in gene regulation. In some cases, these inhibitors may also exert their effects through allosteric mechanisms, where they bind to sites on the protein distinct from the DNA-binding domain, inducing conformational changes that impair the protein's activity. The binding of TIAF-1 inhibitors is stabilized through various non-covalent interactions, including hydrogen bonding, hydrophobic interactions, van der Waals forces, and ionic interactions, ensuring that the inhibitors remain bound to the protein and effectively inhibit its function.
Structurally, TIAF-1 inhibitors exhibit significant diversity, allowing them to engage with specific regions of the TIAF-1 protein with high specificity. These inhibitors often incorporate functional groups such as hydroxyl, carboxyl, or amine groups that facilitate strong interactions through hydrogen bonding and ionic interactions with critical amino acid residues in the protein's binding sites. Additionally, many TIAF-1 inhibitors feature aromatic rings and heterocyclic structures that enhance hydrophobic interactions with non-polar regions of the protein, further stabilizing the inhibitor-protein complex. The physicochemical properties of these inhibitors, including molecular weight, solubility, lipophilicity, and polarity, are carefully optimized to ensure effective binding and stability across various biological environments. By achieving a balance between hydrophilic and hydrophobic regions, TIAF-1 inhibitors can selectively interact with both polar and non-polar areas of the protein, ensuring robust and efficient inhibition of TIAF-1 activity in a range of cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor kinase inhibitor that inhibits the phosphorylation of Smad2, hence preventing downstream signaling. As TIAF-1 is TGF-β1-induced, SB431542 can indirectly affect its expression. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
A selective inhibitor of TGF-β receptor type I/II, which can indirectly influence the expression of TGF-β1-induced proteins like TIAF-1. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
Inhibitor of TGF-β receptor I, affecting the TGF-β signaling pathway. By influencing this pathway, it can modulate the expression of downstream proteins, potentially including TIAF-1. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
Another inhibitor of TGF-β receptor I and II. By affecting the TGF-β signaling cascade, it indirectly modulates the expression of proteins induced by TGF-β1. | ||||||
Smad3 Inhibitor, SIS3 | 1009104-85-1 | sc-222318 | 1 mg | $257.00 | 36 | |
Inhibits Smad3, a critical component of the TGF-β signaling pathway. By inhibiting Smad3, it can impact the expression and activity of downstream proteins, potentially including TIAF-1. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-β receptor I kinase inhibitor that disrupts the TGF-β signaling pathway, potentially affecting the expression of TGF-β1-induced proteins. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
Another inhibitor of TGF-β receptor I, thus affecting the downstream signaling and potentially the expression of TIAF-1. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
Inhibits the TGF-β receptor, affecting downstream signaling. Its influence on the TGF-β pathway can indirectly modulate the expression and activity of TIAF-1. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
While primarily an anti-fibrotic agent, PFD has shown inhibitory effects on TGF-β, and thereby can indirectly influence TGF-β1-induced proteins like TIAF-1. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $31.00 $103.00 $283.00 $978.00 | 2 | |
An anti-allergic drug that has demonstrated inhibitory effects on TGF-β1 release, which can have implications on the expression of proteins like TIAF-1. | ||||||